Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteinsFEJZO, Marlena Schoenberg; SLAMON, Dennis J.The American journal of pathology. 2001, Vol 159, Num 5, pp 1645-1650, issn 0002-9440Article

Effects on Quality of Life of combined trastuzumab and chemotherapy in women with metastatic breast cancerOSOBA, David; SLAMON, Dennis J; BURCHMORE, Michael et al.Journal of clinical oncology. 2002, Vol 20, Num 14, pp 3106-3113, issn 0732-183XArticle

A candidate tumor suppressor gene, H37, from the human lung cancer tumor suppressor locus 3p21.3OH, Juliana J; WEST, Alison R; FISHBEIN, Michael C et al.Cancer research (Baltimore). 2002, Vol 62, Num 11, pp 3207-3213, issn 0008-5472Article

Treatment of meningeal breast cancer xenografts in the rat using an anti-P185/HER2 antibodyBERGMAN, Ira; BARMADA, Mamdouha A; GRIFFIN, Judith A et al.Clinical cancer research. 2001, Vol 7, Num 7, pp 2050-2056, issn 1078-0432Article

The molecular and cellular biology of HER2/neu gene amplification/ overexpression and the clinical development of herceptin (Trastuzumab) therapy for breast cancerPEGRAM, Mark D; KONECNY, Gottfried; SLAMON, Dennis J et al.Cancer treatment and research. 2000, Vol 103, pp 57-75, issn 0927-3042Article

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing : Biologic and Methodologic ConsiderationsSAUTER, Guido; LEE, James; BARTLETT, John M. S et al.Journal of clinical oncology. 2009, Vol 27, Num 8, pp 1323-1333, issn 0732-183X, 11 p.Article

The two single nucleotide polymorphisms in the H37/RBM5 tumour suppressor gene at 3p21.3 correlated with different subtypes of non-small cell lung cancersOH, Juliana J; KOEGEL, Ashley K; PHAN, Diana T et al.Lung cancer. 2007, Vol 58, Num 1, pp 7-14, issn 0169-5002, 8 p.Article

Targeting P13K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKTO'BRIEN, Neil A; MCDONALD, Karen; FINN, Richard S et al.Clinical cancer research (Print). 2014, Vol 20, Num 13, pp 3507-3520, issn 1078-0432, 14 p.Article

3p21.3 tumor suppressor gene H37/Luca15/RBM5 inhibits growth of human lung cancer cells through cell cycle arrest and apoptosisOH, Juliana J; RAZFAR, Ali; DELGADO, Idolina et al.Cancer research (Baltimore). 2006, Vol 66, Num 7, pp 3419-3427, issn 0008-5472, 9 p.Article

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancerHURLEY, Judith; DOLINY, Philomena; REIS, Isildinha et al.Journal of clinical oncology. 2006, Vol 24, Num 12, pp 1831-1838, issn 0732-183X, 8 p.Article

Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancerBYRNE, Jennifer A; BALLEINE, Rosemary L; SLAMON, Dennis J et al.International journal of cancer. 2005, Vol 117, Num 6, pp 1049-1054, issn 0020-7136, 6 p.Article

Ganitumab (AMG 479) Inhibits IGF-II-Dependent Ovarian Cancer Growth and Potentiates Platinum-Based ChemotherapyBELTRAN, Pedro J; CALZONE, Frank J; GUORONG YANG et al.Clinical cancer research (Print). 2014, Vol 20, Num 11, pp 2947-2958, issn 1078-0432, 12 p.Article

AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53KALOUS, Ondrej; CONKLIN, Dylan; LANGERØD, Anita et al.Breast cancer research and treatment. 2013, Vol 141, Num 3, pp 397-408, issn 0167-6806, 12 p.Article

Promoter methylation study of the H37/RBM5 tumor suppressor gene from the 3p21.3 human lung cancer tumor suppressor locusOH, Juliana J; BOCTOR, Baher N; JIMENEZ, Cynthia A et al.Human genetics. 2008, Vol 123, Num 1, pp 55-64, issn 0340-6717, 10 p.Article

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug developmentPARK, John W; KERBEL, Robert S; KELLOFF, Gary J et al.Clinical cancer research. 2004, Vol 10, Num 11, pp 3885-3896, issn 1078-0432, 12 p.Article

Overexpression of AKT2/protein kinase Bβ leads to up-regulation of β1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cellsARBOLEDA, M. Jane; LYONS, John F; KABBINAVAR, Fairooz F et al.Cancer research (Baltimore). 2003, Vol 63, Num 1, pp 196-206, issn 0008-5472, 11 p.Article

Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian CancerKONECNY, Gottfried E; CHEN WANG; GOSTOUT, Bobbie et al.Journal of the National Cancer Institute. 2014, Vol 106, Num 10, issn 0027-8874, 249.1-249.8Article

Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic RegimensVALERO, Vicente; FORBES, John; FUMOLEAU, Pierre et al.Journal of clinical oncology. 2011, Vol 29, Num 2, pp 149-156, issn 0732-183X, 8 p.Article

Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancerKONECNY, Gottfried E; PAULETTI, Giovanni; JÄNICKE, Fritz et al.Breast cancer research and treatment. 2010, Vol 120, Num 2, pp 481-489, issn 0167-6806, 9 p.Article

Cardiovascular risk profile of patients with HER2/neu-positive Breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumabJONES, Lee W; HAYKOWSKY, Mark; PEDDLE, Carolyn J et al.Cancer epidemiology, biomarkers & prevention. 2007, Vol 16, Num 5, pp 1026-1031, issn 1055-9965, 6 p.Article

First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumorsMUNSTER, Pamela N; BRITTEN, Carolyn D; TOLCHER, Anthony W et al.Clinical cancer research. 2007, Vol 13, Num 4, pp 1238-1245, issn 1078-0432, 8 p.Article

Evaluation of HER-2/neu gene amplification and overexpression: Comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimensPRESS, Michael F; SLAMON, Dennis J; FLOM, Kerry J et al.Journal of clinical oncology. 2002, Vol 20, Num 14, pp 3095-3105, issn 0732-183XArticle

Alteration of Topoisomerase II―Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based ChemotherapyPRESS, Michael F; SAUTER, Guido; ROBERT, Nicholas et al.Journal of clinical oncology. 2011, Vol 29, Num 7, pp 859-867, issn 0732-183X, 9 p.Article

ERCC5 Is a Novel Biomarker of Ovarian Cancer PrognosisWALSH, Christine S; OGAWA, Seishi; SANADA, Masashi et al.Journal of clinical oncology. 2008, Vol 26, Num 18, pp 2952-2958, issn 0732-183X, 7 p.Article

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/ triple-negative breast cancer cell lines growing in vitroFINN, Richard S; DERING, Judy; GINTHER, Charles et al.Breast cancer research and treatment. 2007, Vol 105, Num 3, pp 319-326, issn 0167-6806, 8 p.Article